STOCK TITAN

QIAGEN Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-linked Credit Facility

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Very Positive)
Tags

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard QIA) announced today that it has successfully concluded a syndicated revolving credit facility for EUR 400mn with an interest rate linked to the company’s environmental, social and governance (ESG) performance.

The agreement makes QIAGEN the first provider of molecular diagnostics solutions with a sustainability component built into corporate borrowing. It underlines QIAGEN’s commitment to people and planet by creating financial incentives to further integrate sustainability throughout every part of its business.

The facility will run for three years and each lender will be able to extend this period by one year two times. It replaces a facility of the same amount that runs until December 2021 and will be used for general corporate purposes including potential acquisitions. One factor determining the new facility’s credit margin will be QIAGEN’s sustainability rating, as assigned by ISS-ESG. This independent and highly regarded sustainability-ratings agency in July 2020 awarded QIAGEN its top-flight “Prime” rating.

“Our mission to make improvements in life possible includes sustainable business practices,” said Roland Sackers, Chief Financial Officer of QIAGEN. “By linking this new credit facility to our sustainability rating, we are creating a new incentive to further foster and embed sustainability in all business areas. An improved ESG rating triggers interest-margin gains and QIAGEN will donate any money saved this way to sustainable causes.”

The syndicated credit facility is provided by a group of eleven core relationship banks and syndication was significantly oversubscribed. Deutsche Bank AG and UniCredit Bank AG were mandated as coordinators with Deutsche Bank AG acting as the Documentation and Facility Agent and UniCredit Bank AG as the sustainability coordinator.

Please find the full press release here

Qiagen NV

NYSE:QGEN

QGEN Rankings

QGEN Latest News

QGEN Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Netherlands
Venlo

About QGEN

qiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.